Abbott Labs Q1 2025 Financial Highlights

Abbott Laboratories has announced a robust start to 2025, with first-quarter revenue climbing to $10.4 billion, marking a 4% increase from the previous year. The company's net earnings soared to $1.3 billion, reflecting an 8.2% growth, while diluted earnings per share (EPS) rose by 8.6% to $0.76.

Leadership Insights

"Abbott's diversified business model continues to drive top-tier sales and EPS growth," stated CEO Robert Ford. He emphasized the company's ability to navigate uncertainty and sustain growth, attributing success to strategic diversification and execution.

2025 Outlook

Reaffirming its 2025 guidance, Abbott projects organic sales growth between 7.5% and 8.5%, with an adjusted operating margin of 23.5% to 24.0% of sales. Adjusted diluted EPS is expected to range from $5.05 to $5.25, signaling confidence in continued financial health and performance.